|
|
Vol. 14.18 – 18 September, 2025
|
|
|
|
|
|
|
|
Investigators developed 4-mercaptobenzoic acid modified copper nanozymes to simultaneously combat bacterial infections and toxin-triggered immune overactivation. [Advanced Science]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
|
|
Researchers sorted epithelial and endothelial cell populations based on their differential surface markers from normal and bronchopulmonary dysplasia human lungs.
[American Journal of Physiology-Lung Cellular and Molecular Physiology]
|
|
|
|
|
|
Scientists revealed the therapeutic value of the Cu ionophore elesclomol for treating KRASG12-mutant–driven lung adenocarcinoma.
[Cancer Research]
|
|
|
|
|
|
The authors investigated the mechanism by which SIRT1 activity is increased and the role of pSIRT1 in the chemoresistance of KRASMut lung cancer cells.
[Experimental & Molecular Medicine]
|
|
|
|
|
|
Researchers demonstrated that polo-like kinase 1 (PLK1) phosphorylation of pyruvate dehydrogenase (PDH) A1 at threonine 57 drives its protein degradation via mitophagy activation.
[Oncogene]
|
|
|
|
|
|
The authors found that propofol impeded lung cancer progression and glycolysis. Additionally, propofol curbed the triosephosphate isomerase 1 (TPI1) protein and increased TPI1 ubiquitination modification. [Biochemical Genetics]
|
|
|
|
|
|
|
|
Scientists synthesize contemporary findings on the molecular mechanisms by which lncRNAs influence major oncogenic cascades in NSCLC. [Cancer Gene Therapy]
|
|
|
|
|
|
|
|
Helmholtz Munich and Parse Biosciences announced a strategic partnership to generate the world’s broadest lung disease perturbation atlas, powered by Parse Biosciences’ GigaLab platform. [Parse Biosciences]
|
|
|
|
|
|
|
|
September 28-October 1, 2025 St. Julian’s, Malta
|
|
|
|
|
|
|
|
|
|
|
Boston University – Boston, Massachusetts, United States
|
|
|
|
|
|
|
|
|
Henry Ford Health + Michigan State – Detroit, Michigan, United States
|
|
|
|
|
|
|
University of Alabama at Birmingham – Birmingham, Alabama, United States
|
|
|
|
|
|
|
Fred Hutchinson Cancer Center – Seattle, Washington, United States
|
|
|
|
|
|